The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Feature|Articles|November 13, 2025
Day 1 Recap: Elevate-Derm Fall Conference
Listen
0:00 / 0:00
Key Takeaways
- Dupilumab significantly enhances growth and reduces corticosteroid use in children with severe atopic dermatitis, as presented at Elevate-Derm.
- New therapeutic strategies for dermatological conditions include low-dose oral minoxidil, off-label JAK inhibitors, Thiamidol, and delgocitinib.
Catch up on coverage from the first day of the 2025 Elevate-Derm Fall Conference.
Advertisement
To stay informed with the latest conference insights, follow us on social media and
Previewing the 2025 Elevate-Derm Fall Conference
Matthew Brunner, MHS, PA-C, discusses upcoming highlights of the 6th annual meeting for dermatology NPs and PAs.
Dupilumab Demonstrates Positive Effects on TCS Use, Growth in Pediatric Patients
A poster presented at Elevate-Derm found dupilumab significantly enhanced growth and reduces corticosteroid use in children with severe atopic dermatitis.
Topical and Systemic Tools Expand Options for Hair Loss, Pigmentary Disorders, and Hand Eczema
Victoria Garcia-Albea, NP, outlined evolving therapeutic strategies at Elevate-Derm Fall, highlighting low-dose oral minoxidil, off-label JAK inhibition for frontal fibrosing alopecia, Thiamidol in hyperpigmentation, and delgocitinib for chronic hand eczema.
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
FDA Revises TB Evaluation Guidance for SKYRIZI
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
5